| Project/Area Number |
15K10965
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Emergency medicine
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
Motoi Okada 旭川医科大学, 医学部, 准教授 (80431427)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
藤田 智 旭川医科大学, 医学部, 教授 (10173428)
西浦 猛 旭川医科大学, 医学部, 客員助教 (90567041)
柏木 友太 旭川医科大学, 医学部, 助教 (70648336)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 心不全 / β遮断薬 / 敗血症 / テロメア / 敗血症性心不全 / カルベジロール / CLP / 敗血症性心筋症 |
|---|
| Outline of Final Research Achievements |
we confirmed the effectiveness of the carvedilol for anti-apoptosis and maintain of the telomeric length with the oxidized cultured cardiomyoblast cell. By the experiment using the mouse CLP model, a suppressant effect and a life prognosis improvement effect were shown a cardiac dysfunction in the carvedilol group. We recognized an expression drop of p53 with the myocardium, expression increase of pgc-1a, tert in the carvedilol group, and mitochondria function improved it more. Even telomeric Q-FISH analysis in a white blood cell accepted extension of the telomere length.
In treatment of the heart failure sepsis-related than the above, carvedilol can expect the restraint of the myocardium mitochondria dysfunction, cardioprotection action heart, a life prognosis improvement effect through the improvement of the energy metabolism.
|
